Biosimilars in Dermatology

Biosimilars are biological therapeutics that resembles the same as specific reference product. Biosimilars of the tumor necrosis factor alpha inhibitors infliximab and etanercept are previously accepted and available for dermatological analysis. To increase market and enhance evidence for Biosimilars, proper information of the specific products given to each patient is essential and should preferably be included in patient record. present information doesn't accept against the use of Biosimilars but   subsequent change of Biosimilars should be considered properly.

 

  • Track 1-1 Etanercept
  • Track 2-2 Infliximab
  • Track 3-3 Physicochemical and functional properties
  • Track 4-4 Drug development

Related Conference of Dermatology